-+ 0.00%
-+ 0.00%
-+ 0.00%

MATCHPOINT THERAPEUTICS ANNOUNCES $150 MILLION SERIES B FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS ORAL SMALL MOLECULES FOR AUTOIMMUNE AND INFLAMMATORY DISEASES

Reuters·10/07/2026 11:00:09

Please log in to view news